Email Updates

Search form

You are here

Investment in Women-Focused PrEP R&D, 2017

Thursday, October 25, 2018

Out of the US$63 million invested in PrEP overall, US$16 million (or 25 percent) was for research explicitly focused on women. Most of this research was preclinical, with an emphasis on discreet products with long-acting formulations, e.g., PrEP implant studies and long-acting injectables. Almost 30 percent of the implementation studies focused on the uptake of and adherence to oral PrEP in high-risk women, and 15 percent focused on PrEP for pregnant and breastfeeding women.

The full report, HIV Prevention Research & Development Investments 2017: Investing to end the epidemic, is available for download. And all the graphics are available as well.